Form 4: Acelyrin Chief Legal Officer Acquires 125,000 Shares Through Restricted Stock Units

Acelyrin's Chief Legal Officer, Amar Murugan, acquired 125,000 shares of common stock through the vesting of restricted stock units.

Summary

• Amar Murugan, the Chief Legal Officer of Acelyrin, Inc., acquired 125,000 shares of common stock on January 23, 2025.
• The acquisition was through the vesting of restricted stock units (RSUs).
• These RSUs vest in twelve equal quarterly installments over three years, starting March 15, 2025.
• The vesting schedule continues on June 15, September 15, and December 15 of each year, contingent on Murugan's continued service.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to executive compensation, which is generally viewed positively as it aligns management's interests with shareholders. There are no indications of any negative issues.

Positives

• The acquisition of shares by a key executive demonstrates confidence in the company's future.
• The vesting schedule incentivizes long-term commitment from the Chief Legal Officer.

Future Outlook

The vesting of the remaining RSUs is contingent on the Chief Legal Officer's continued service over the next three years.

Industry Context

This is a standard practice for executive compensation in publicly traded companies, using equity to align management's interests with those of shareholders.

Comparison to Industry Standards

• The use of restricted stock units (RSUs) for executive compensation is a common practice among publicly traded companies, including those in the biotechnology sector like Acelyrin.
• Companies such as Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize RSUs as part of their executive compensation packages.
• The vesting schedule of three years with quarterly installments is also a typical structure to ensure long-term commitment from executives.

Stakeholder Impact

• The acquisition of shares by the Chief Legal Officer may be viewed positively by shareholders as it indicates confidence in the company's future.

Key Dates

Keywords

Acelyrin, stock, restricted stock units, RSU, insider trading, share acquisition, executive compensation, vesting